PatientsVille.com Logo

PLATELET COUNT DECREASED and Voltaren

PatientsVille

PLATELET COUNT DECREASED Symptoms and Causes

Platelets are little pieces of blood cells. Platelets help wounds heal and prevent bleeding by forming blood clots. Your bone marrow makes platelets. Problems can result from having too few or too many platelets, or from platelets that do not work properly.

If your blood has a low number of platelets, it is called thrombocytopenia. This can put you at risk for mild to serious bleeding. If your blood has too many platelets, you may have a higher risk of blood clots. With other platelet disorders, the platelets do not work as they should. For example, in von Willebrand Disease, the platelets cannot stick together or cannot attach to blood vessel walls. This can cause excessive bleeding.

Treatment of platelet disorders depends on the cause.

NIH: National Heart, Lung, and Blood Institute

Check out the latest treatments for PLATELET COUNT DECREASED

PLATELET COUNT DECREASED treatment research studies

Voltaren clinical trials, surveys and public health registries


Find Drug Side Effect reports



Voltaren Side Effects

Off Label Use (256)
Dyspnoea (171)
Therapeutic Response Unexpected (136)
Blood Creatinine Increased (129)
Aspartate Aminotransferase Increased (122)
Pain (115)
Alanine Aminotransferase Increased (114)
Nausea (114)
Pyrexia (112)
Erythema (108)
Blood Urea Increased (108)
Dizziness (107)
C-reactive Protein Increased (105)
Blood Pressure Decreased (105)
Renal Failure Acute (103)
Haemoglobin Decreased (85)
Blood Lactate Dehydrogenase Increased (84)
Anaemia (84)
Underdose (83)
Abdominal Pain Upper (81)
Diarrhoea (80)
Rash (80)
Oedema Peripheral (77)
Pruritus (74)
Loss Of Consciousness (74)
Shock (73)
Malaise (72)
Gastric Ulcer (72)
Vomiting (70)
Abdominal Pain (70)
Fall (64)
Hypotension (62)
Pain In Extremity (59)
Gastrointestinal Haemorrhage (57)
Headache (56)
Overdose (56)
Anaphylactic Shock (56)
Asthenia (54)
Blood Alkaline Phosphatase Increased (54)
Depressed Level Of Consciousness (53)
Chest Pain (52)
Melaena (51)
Blood Creatine Phosphokinase Increased (51)
Blood Bilirubin Increased (49)
Back Pain (49)
Disseminated Intravascular Coagulation (49)
Haematemesis (49)
Liver Disorder (49)
Blister (48)
Hypertension (47)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

It seems as though after I have applied the Voltaren to my hands and feet a couple of hours later or even the next day, I get a migrane headache and slowly but very surely all my joints, from my neck down to my elbows, knees, hips are especially pain

What is dyspnoae

Marax was the asthma the best medicine for me to treat asthma. Inhalers do not work. Apparently centuries of using the contents of Marax with success does not count with the FDA. Shame on them. Bring back this medication.

can platelete count reduced drastically to 1000 on medication of sibelium 5 mg for 2 weeks.

I just started taking lisinopril and am also staying very tired. Dizziness and lightheadness are my biggest problems right now.I am taking this with cardura and zoloft, so it may not count here. But i wanted to share my input and after reading the c

had my first shot of aranesp one week ago for anemia , i have renal failure, I'm 62 , and I am a working nurse. I will be getting aranesp every 2 weeks if my blood count is less than 11. well out of no where I have becom

1st day was hell, had about every side effect in the book. 2nd day was better, side effects decreased greatly 5th day is going well so far- feeling a little 'edgy & apprehensive' but better than the alternative

After a few weeks on Piascledine, knee and back pain decreased considerably with no side effects noted. Not perfect, but much better. I was walking like an old man.

After a urinalisis the doctor told me there were no white blood cells, only red blood cells in urine. drew blood and had cat scan and revealed a 7mm kidney stone. but i'm worried about having no white blood cell count in my urine

After consuming myonal for two days, i suffer from jaundice... my bilirubin counts wer of the roof so as my ALP, and ALT count.. hmm...

An addition to Frances Wedderburn's side effects from Januvia, some of my Liver Enzymes became elevated. They decreased when checked 10 days after stopping Januvia. Diarrhoea continues

Been taking Omnic or about 2months and have experienced decreased semen production. Is this a common side effect of taking Omnic or a new symptom of a slightly enlarged prostate? Thanks

PLATELET COUNT DECREASED Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Study Comparing a Generic Diclofenac Sodium Topical Gel, 1% to Voltaren in the Treatment of Subjects With Osteoarthritis of the Knee
Condition: Osteoarthritis
Interventions: Drug: Diclofenac Sodium Topical Gel, 1%;   Drug: Voltaren Topical Gel, 1%;   Drug: Vehicle Diclofenac Sodium Topical Gel
Outcome Measure: WOMAC Pain Score
2 Recruiting Safety Study of Flector Patch in Children With Minor Soft Tissue Injuries
Condition: Athletic Injuries
Intervention: Drug: Diclofenac hydroxyethylpyrrolidine
Outcome Measures: Dermatologic assessment at the patch application site;   Investigator assessment of the global response to therapy on a 5-point scale;   Patient assessment of pain on a 6-point scale;   Plasma concentration of diclofenac
3 Recruiting An Investigator Initiated, Within-Subject, Proof of Concept Study to Assess the Analgesic Efficacy and Safety of Voltaren Gel (1% Diclofenac Sodium) Compared to Placebo in Subjects Experiencing Delayed Onset Muscle Soreness
Condition: Delayed Onset Muscle Soreness
Interventions: Drug: 1% diclofenac sodium gel;   Drug: Placebo
Outcome Measure: To assess analgesic efficacy of Topical Voltaren® gel compared to placebo
4 Recruiting Treatment of Knee Pain With Topical Diclofenac Cream 8% or Diclofenac Gel 1%
Conditions: Knee Pain Chronic;   Knee Injuries
Interventions: Drug: Diclofenac Cream 8%;   Drug: Diclofenac Gel 1%
Outcome Measure: Descrete Response Scale Pain Scores
5 Unknown  Comparison of the Effect of Etoricoxib and Diclofenac on Early Morning Activity in Rheumatoid Arthritis (RA)
Condition: Rheumatoid Arthritis
Interventions: Drug: Etoricoxib;   Drug: Diclofenac
Outcome Measures: To explore the effect of Etoricoxib compared to Diclofenac on physical activity in RA subjects with Early morning pain and stiffness.;   To explore the effect of Etoricoxib compared to Diclofenac on average daily pain scores, fatigue scores, and quality of life.
6 Recruiting Efficacy of Diclofenac on Pain During Endometrial Sampling
Condition: Abnormal Uterine Bleeding Unrelated to Menstrual Cycle
Interventions: Drug: Diclofenac Potassium;   Drug: Folic Acid
Outcome Measure: Effectiveness of Diclofenac Potassium for additional acute pain control in patient undergoing fractional curettage under paracervical block due to abnormal uterine bleeding
7 Recruiting A Multicenter Efficacy Study of a Diclofenac+Menthol Gel in Subjects With Ankle Sprain
Condition: Ankle Sprain
Interventions: Drug: 1% diclofenac sodium plus 3% menthol;   Drug: 1% diclofenac sodium plus 0.09% menthol;   Drug: 3% menthol;   Drug: Placebo with 0.09% menthol gel
Outcome Measures: AUC (1-3 days);   Pain Intensity Difference (PID) on movement;   PID at rest;   Pain Relief Score (PRS);   Sum of Pain Intensity Difference (SPID);   Time of Onset of Pain Relief (TOPR);   Time of Onset of Meaningful Pain Relief (TOMR);   Time of Onset of Cooling Sensation (TOCS);   Total Pain Relief (TOTPAR);   Skin Temperature;   Ankle Swelling;   Time to complete Recovery;   Patient's Global Assessment in Response to Treatment (PGART);   Adverse events (AEs)
8 Recruiting Effects of Topical Diclofenac on Tumor Metabolism
Condition: Actinic Keratoses
Intervention: Drug: 3% diclofenac in 2.5% hyaluronic acid gel
Outcome Measures: Lactate level in skin biopsies of actinic keratoses;   Lactate level in skin biopsies of healthy skin in a subpopulation;   Glycolysis-relevant proteins evaluated using PCR and Westernblot techniques;   Metabolic changes (e.g. glucose, amino acids)
9 Not yet recruiting Supersaturation and Precipitation of Diclofenac in the Stomach of Healthy Volunteers
Condition: Supersaturation and Precipitation in the Stomach
Intervention: Drug: Diclofenac potassium 50 mg
Outcome Measure: Area under the Concentration - Time Curve
10 Unknown  Use of Etoricoxib Compared to Diclofenac in the Perioperative Treatment of Patients After Total Hip Arthroplasty
Conditions: Coxarthrosis;   Arthroplasties Hip Replacement;   Perioperative Blood Loss
Interventions: Drug: Etoricoxib;   Drug: Diclofenac
Outcome Measure:
11 Recruiting Diclofenac for Submassive PE
Condition: Pulmonary Embolism
Interventions: Drug: Diclofenac;   Drug: Placebo
Outcome Measure: Right ventricular dysfunction assessed by transthoracic echocardiography
12 Not yet recruiting In Vivo Inhibition Profile of CYP2C9 by Pineapple Juice
Condition: Healthy Volunteers
Intervention: Dietary Supplement: pineapple juice (Carrefour n°1) 500 ml/day 5 days
Outcome Measures: a) AUC 4-OH-diclofenac / AUC diclofenac quantified in plasma, on days 1 (without pineapple juice) and 11 (after pretreatment with pineapple juice);   (b) AUC 4-OH-diclofenac/ AUC diclofenac quantified in urine, on days 1 (without pineapple juice) and 11 (after pretreatment with pineapple juice)
13 Unknown  The Comparison Between the Therapeutic Affect of Intravitreal Diclophenac and Triamcinolone in Persistent Uveitic Cystoids Macular Edema
Conditions: Uveitis;   Cystoid Macular Edema
Interventions: Drug: Diclophenac;   Drug: Triamcinolone
Outcome Measure:
14 Recruiting Efficacy and Safety of Diclofenac DDEA 2.32 % in Patient Suffering From Knee Osteoarthritis (OA)
Condition: Osteoarthritis, Knee
Intervention: Drug: diclofenac diethylamine, DDEA 2.32% gel
Outcome Measures: Measure: Pain On Movement (POM);   Measure POM regarding onset of efficacy
15 Recruiting Intramuscular Diclofenac in the Prevention of Post-ERCP Pancreatitis
Condition: Post ERCP Pancreatitis
Interventions: Drug: Diclofenac;   Drug: normal saline
Outcome Measure: Incidence of post ERCP pancreatitis
16 Unknown  Efficacy of Diclofenac BCG Irrigations
Condition: Bladder Cancer
Interventions: Drug: Abitren;   Drug: Placebo
Outcome Measures: Change in weekly COOP Questionnaire 1;   Change in weekly COOP Questionnaire 2;   Change in weekly COOP Questionnaire 3;   Change in weekly Bladder symptoms Questionnaire;   Change in weekly time schedule questionnaire
17 Recruiting Post ERCP Pancreatitis Prevention in Average Risk Patients
Condition: Pancreatitis
Intervention: Procedure: Ceftazidime
Outcome Measure: Incidence of PEP in the group of patients receiving Ceftazidime versus incidence of PEP in the group of patients receiving Diclophenac potassium
18 Unknown  Intravitreal Diclofenac Versus Avastin as Primary Treatment of Diffuse Diabetic Macular Edema
Condition: Diffuse Diabetic Macular Edema
Interventions: Drug: Bevacizumab;   Drug: Diclofenac
Outcome Measure:
19 Not yet recruiting Diclofenac add-on to Treatment as Usual for Suicidal Patients
Condition: Depression Suicidal
Interventions: Drug: sugar pill;   Drug: Diclofenac
Outcome Measures: Suicide Assessment Scale (differences in scores before and after treatment);   Montgomery Asberg Rating Scale (differences in scores before and after treatment);   Barratt Impulsiveness Scale (differences in scores before and after treatment);   Montgomery Asberg depression Ratin scale (changes in suicidality item before and after treatment);   Montgomery Asberg Rating Scale (changes in concentration item before and after treatment);   Comprehensive Psychopathological Rating Scale (changes in aggressive feelings item before and after treatment);   Comprehensive Psychopthological Rating Scale (changes in fatigue item before and after treatment)
20 Recruiting OASIS: Osteoarthritis Sensitivity Integration Study
Conditions: Osteoarthritis;   Chronic Pain
Intervention: Drug: duloxetine, diclofenac
Outcome Measure: Pain